Alterations in the immune system persist after one year of convalescence in severe COVID-19 patients
暂无分享,去创建一个
E. Urcelay | E. Anguita | L. Espino-Paisán | Judith Abarca-Zabalía | Myriam Calle-Rubio | C. Ramos-Acosta | Adela González-Jiménez | A. R. Lopez-Pastor | Tomás Fariña | Laura Espino-Paisán | Andrea R. Lopez-Pastor
[1] S. Della Bella,et al. Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications , 2022, Frontiers in Immunology.
[2] L. Joosten,et al. Multi-Omics Integration Reveals Only Minor Long-Term Molecular and Functional Sequelae in Immune Cells of Individuals Recovered From COVID-19 , 2022, Frontiers in Immunology.
[3] Tao Jiang,et al. Identification of Distinct Immune Cell Subsets Associated With Asymptomatic Infection, Disease Severity, and Viral Persistence in COVID-19 Patients , 2022, Frontiers in Immunology.
[4] E. Mace. Profiling natural killers in COVID-19 , 2022, Journal of Allergy and Clinical Immunology.
[5] A. Antón,et al. COVID-19 Clinical Profile in Latin American Migrants Living in Spain: Does the Geographical Origin Matter? , 2021, Journal of clinical medicine.
[6] Haiyoung Jung,et al. SARS-CoV-2 peptides bind to NKG2D and increase NK cell activity , 2021, Cellular Immunology.
[7] E. Bargagli,et al. NK and T Cell Immunological Signatures in Hospitalized Patients with COVID-19 , 2021, Cells.
[8] S. Jiménez,et al. Increased severity in SARS-CoV-2 infection of minorities in Spain , 2021, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.
[9] M. Kubo,et al. SARS-CoV-2 infection causes immunodeficiency in recovered patients by downregulating CD19 expression in B cells via enhancing B-cell metabolism , 2021, Signal Transduction and Targeted Therapy.
[10] S. Barry,et al. Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection , 2021, BMC Medicine.
[11] Héctor Martínez Alonso,et al. Socio-Demographic Health Determinants Are Associated with Poor Prognosis in Spanish Patients Hospitalized with COVID-19 , 2021, Journal of General Internal Medicine.
[12] P. Kaminski,et al. Angiogenic Properties of NK Cells in Cancer and Other Angiogenesis-Dependent Diseases , 2021, Cells.
[13] Baoju Wang,et al. Analysis of the Long-Term Impact on Cellular Immunity in COVID-19-Recovered Individuals Reveals a Profound NKT Cell Impairment , 2021, mBio.
[14] A. Douiri,et al. COVID-19 and ethnicity:has history repeated itself? , 2021, Thorax.
[15] C. Brightling,et al. Alterations in T and B cell function persist in convalescent COVID-19 patients , 2021, Med.
[16] R. López-Vélez,et al. COVID-19 and geographical area of origin , 2020, Clinical Microbiology and Infection.
[17] F. Fathi,et al. Immune system changes during COVID-19 recovery play key role in determining disease severity , 2020, International journal of immunopathology and pharmacology.
[18] B. Reinius,et al. Natural killer cell immunotypes related to COVID-19 disease severity , 2020, Science Immunology.
[19] G. Jiang,et al. Activation status of CD56dim natural killer cells is associated with disease activity of patients with systemic lupus erythematosus , 2020, Clinical Rheumatology.
[20] E. Malmierca,et al. Epidemiological characteristics of the COVID-19 outbreak in a secondary hospital in Spain , 2020, American Journal of Infection Control.
[21] F. Zheng,et al. The Increased Ratio of Blood CD56bright NK to CD56dim NK Is a Distinguishing Feature of Primary Sjögren's Syndrome , 2020, Journal of immunology research.
[22] J. Mikes,et al. Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19 , 2020, Cell Reports Medicine.
[23] C. Pellegrini,et al. NKG2A and COVID-19: another brick in the wall , 2020, Cellular & Molecular Immunology.
[24] Antonio Uccelli,et al. CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis , 2020, Journal of clinical medicine.
[25] R. Bruno,et al. Unique immunological profile in patients with COVID-19 , 2020, Cellular & Molecular Immunology.
[26] Taojiao Wang,et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.
[27] Z. Tian,et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients , 2020, Cellular & Molecular Immunology.
[28] H. Favoreel,et al. NKp44-NKp44 Ligand Interactions in the Regulation of Natural Killer Cells and Other Innate Lymphoid Cells in Humans , 2019, Front. Immunol..
[29] H. Hocine,et al. Natural cytotoxicity receptor splice variants orchestrate the distinct functions of human natural killer cell subtypes , 2015, Nature Communications.
[30] T. Mak,et al. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity , 2011, Proceedings of the National Academy of Sciences.
[31] R. Welsh,et al. Natural killer cells act as rheostats modulating antiviral T cells , 2011, Nature.
[32] P. J. Norris,et al. Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection , 2011, Proceedings of the National Academy of Sciences.
[33] H. Ljunggren,et al. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus , 2011, The Journal of experimental medicine.
[34] A. Angulo,et al. IL-12-Dependent Inducible Expression of the CD94/NKG2A Inhibitory Receptor Regulates CD94/NKG2C+ NK Cell Function1 , 2009, The Journal of Immunology.
[35] J. R. Lapa e Silva,et al. Another brick in the wall. , 2002, Sao Paulo medical journal = Revista paulista de medicina.